Shionogi & Co.,Ltd. Logo

Shionogi & Co.,Ltd.

A research-driven pharmaceutical firm creating drugs, diagnostics, and devices for global health.

4507 | T

Overview

Corporate Details

ISIN(s):
JP3347200002
LEI:
Country:
Japan
Address:
大阪市中央区道修町3丁目1番8号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Shionogi & Co., Ltd. is a research-driven pharmaceutical company focused on the discovery, development, manufacturing, and marketing of pharmaceuticals, diagnostic reagents, and medical devices. With a history of over 140 years, the company is dedicated to creating innovative products and services that deliver value to patients and society globally. As a drug discovery-based organization, Shionogi leverages its robust research and development pipeline to address unmet medical needs and contribute to the health of people worldwide.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-07 03:07
Registration Form
確認書
Japanese 8.9 KB
2025-11-07 03:05
Interim Report
半期報告書-第161期(2025/04/01-2026/03/31)
Japanese 327.3 KB
2025-09-25 08:53
M&A Activity
訂正臨時報告書
Japanese 48.0 KB
2025-06-19 09:24
Post-Annual General Meeting Information
臨時報告書
Japanese 30.7 KB
2025-06-19 09:14
Governance Information
内部統制報告書-第160期(2024/04/01-2025/03/31)
Japanese 30.2 KB
2025-06-19 09:12
Registration Form
確認書
Japanese 8.9 KB
2025-06-19 09:10
Annual Report
有価証券報告書-第160期(2024/04/01-2025/03/31)
Japanese 2.5 MB
2025-06-19 08:07
M&A Activity
公開買付報告書
Japanese 41.6 KB
2025-06-19 06:40
Major Shareholding Notification
大量保有報告書
Japanese 61.0 KB
2025-06-18 08:49
Share Issue/Capital Change
臨時報告書
Japanese 41.9 KB
2025-06-04 08:39
M&A Activity
訂正公開買付届出書
Japanese 258.4 KB
2025-05-28 08:38
M&A Activity
訂正公開買付届出書
Japanese 262.0 KB
2025-05-08 05:52
M&A Activity
公開買付届出書
Japanese 530.2 KB
2025-05-07 09:12
M&A Activity
臨時報告書
Japanese 50.3 KB
2024-11-08 02:44
Interim Report
確認書
Japanese 9.0 KB

Automate Your Workflow. Get a real-time feed of all Shionogi & Co.,Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Shionogi & Co.,Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Shionogi & Co.,Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

ArcticZymes Technologies Logo
Develops novel enzymes from Arctic organisms for diagnostics, therapeutics, and biopharma.
Norway
AZT
Arcturus Therapeutics Holdings Inc. Logo
Develops mRNA therapeutics and vaccines for rare respiratory, liver, and infectious diseases.
United States of America
ARCT
Arcus Biosciences, Inc. Logo
A clinical-stage biopharma developing small molecule and antibody combination therapies for cancer.
United States of America
RCUS
Arcutis Biotherapeutics, Inc. Logo
Develops and commercializes non-steroidal therapies for immune-mediated skin diseases.
United States of America
ARQT
ARDELYX, INC. Logo
Biopharma developing first-in-class drugs for cardiorenal and GI diseases like IBS-C and CKD.
United States of America
ARDX
ARECOR THERAPEUTICS PLC Logo
Biopharma firm enhancing drugs via reformulation for diabetes and pharmaceutical partners.
United Kingdom
AREC
argenx SE Logo
Develops first-in-class antibody therapies for severe autoimmune diseases.
Netherlands
1AE
Armata Pharmaceuticals, Inc. Logo
Developing bacteriophage therapeutics for antibiotic-resistant infections.
United States of America
ARMP
AroCell AB Logo
Develops and markets diagnostic tests for monitoring cancer and bacterial diseases.
Sweden
AROC
ArriVent BioPharma, Inc. Logo
A clinical-stage biopharma developing in-licensed oncology drugs for difficult-to-treat diseases.
United States of America
AVBP

Talk to a Data Expert

Have a question? We'll get back to you promptly.